Aducanumab for Alzheimer's disease: An update


  • Thaarvena Retinasamy Neuropharmacology Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor, Malaysia.
  • Mohd. Farooq Shaikh Neuropharmacology Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor, Malaysia.



Alzheimer's disease, Amyloid beta, Aducanumab, Aduhlem, Neurodegeneration


The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its accelerated approval pathway. It has given some hope to patients suffering from AD around the world. Aducanumab is an antibody that targets one of the well-known key culprits of this disease, known as amyloid-beta (Aβ). The journey of Aducanumab was bumpy, and there are controversies around the rapid approval of this drug AD treatment. This article highlights the potential of Aducanumab in AD, its mode of action and controversies around it.


Alzheimer's disease facts and figures. (2018). Alzheimer's & Dementia, 14(3), 367-429.

An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., Levey, A. I., Lah, J., Seyfried, N. T., Legido-Quigley, C., O'Brien, R., & Thambisetty, M. (2018). Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's & Dementia, 14(3), 318-329.

Bachmann, M. F., Jennings, G. T., & Vogel, M. (2019). A vaccine against Alzheimer's disease: anything left but faith? Expert Opinion on Biological Therapy, 19(1), 73-78.

Crehan, H., & Lemere, C. A. (2016). Chapter 7 - Anti-Amyloid-β Immunotherapy for Alzheimer's Disease. In M. S. Wolfe (Ed.), Developing Therapeutics for Alzheimer's Disease (pp. 193-226). Academic Press.

Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer's Research & Therapy, 13(1), 98.

Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016). Drug development in Alzheimer's disease: the path to 2025. Alzheimer's research & therapy, 8(1), 39.

Cummings, J. L., Morstorf, T., & Zhong, K. (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy, 6(4), 37.

Dunstan, R., Bussiere, T., Fahrer, D., Quigley, C., Zhang, X., Themeles, M., Engber, T., Rhodes, K., Arastu, M., & Li, M. (2011). Quantitation of beta-amyloid in transgenic mice using whole slide digital imaging and image analysis software. Alzheimer's & Dementia, 7(4, Supplement), S700.

Farrimond, L. E., Roberts, E., & McShane, R. (2012). Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open, 2(3), e000917.

Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016). First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia, 2(3), 169-176.

Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 27(1), 18-18.

Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020). The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathologica, 140(4), 417-447.

Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021). Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer's & Dementia, 17(4), 696-701.

Marasco, R. A. (2020). Current and evolving treatment strategies for the Alzheimer disease continuum. American Journal of Managed Care, 26(8 Suppl), S167-s176.

Mullard, A. (2021). Landmark Alzheimer's drug approval confounds research community. Nature, 594(7863), 309-310.

Rajan, K. B., Wilson, R. S., Weuve, J., Barnes, L. L., & Evans, D. A. (2015). Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology, 85(10), 898.

Schneider, L. (2020). A resurrection of aducanumab for Alzheimer's disease. The Lancet Neurology, 19(2), 111-112.

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., & Kivipelto, M. (2014). Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 275(3), 251-283.

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H., … Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537(7618), 50-56.

Siemers, E. (2015). Drug Development in AD: Point of View from the Industry. Journal of Prevention of Alzheimer's Disease, 2(4), 216-218.

Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016). Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxidative medicine and cellular longevity, 2016, 7361613-7361613.




How to Cite

Retinasamy, T. and Shaikh, M. F. (2021) “Aducanumab for Alzheimer’s disease: An update”, Neuroscience Research Notes, 4(2), pp. 17–20. doi: 10.31117/neuroscirn.v4i2.81.